MedTrace Logo

Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza

NCT05095545 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2021-10-27

No results posted yet for this study

Summary

Assessment of the effect reached with the different doses of AV5080 on the duration and severity of influenza symptoms based on the incidence of their resolution within 96 hours from study treatment initiation compared to Placebo.

The absence of influenza symptoms or their reduction to mild severity for at least 24 hours indicates the resolution of influenza.

Conditions

Interventions

DRUG

AV5080

Hard gelatin capsules with a white body

OTHER

Placebo

Hard gelatin capsules with a white body

Sponsors & Collaborators

  • Viriom

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-13
Primary Completion
2019-08-07
Completion
2019-08-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095545 on ClinicalTrials.gov